In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Crealta Pharmaceuticals

https://crealtapharma.squarespace.com/

Latest From Crealta Pharmaceuticals

Horizon Ramps Teprotumumab Launch Plans Into High Gear

With US FDA action on teprotumumab anticipated in March, Horizon has assembled a 100-person commercial team to begin educating physicians and payers on the rare autoimmune condition thyroid eye disease (TED).

Sales & Earnings Launches

A Penny Saved: Why Delaying 340B Pricing Rule Is Good News For Companies Like Horizon

HRSA proposes another delay to effective date of final rule on calculating the ceiling prices for drugs sold to 340B program. Agency also appears ready to reconsider the 'penny pricing' policy that rule would codify.

Market Access Healthcare Systems

Deal Watch: Otsuka’s Neurovance Buy Adds ADHD Candidate To CNS Pipeline

Otsuka's purchase of Neurovance is part of a larger strategy to replace revenues lost to patent expiration of Abilify. Meanwhile, its Japanese counterpart Takeda is overhauling its R&D engine with help from contract manufacturer Bushu.

Deals M & A

Raptor Buy Bolsters Horizon's Orphan Business As Primary Care Foots The Bill

Horizon will boost its orphan drug business through the acquisition of Raptor, using a combination of debt and cash from its primary care and other assets to fund the transaction.

Commercial Companies
See All

Company Information

  • Other Names / Subsidiaries
    • Savient Pharmaceuticals, Inc. (SVNT)
    • Bio-Technology General Corporation
UsernamePublicRestriction

Register